A reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. Reverse transcriptases are used by viruses such as HIV and hepatitis B to replicate their genomes, by  retrotransposon mobile genetic elements to proliferate within the host genome, and by eukaryotic cells to extend the telomeres at the ends of their linear chromosomes. Contrary to a widely held belief, the process does not violate the flows of genetic information as described by the classical central dogma, as transfers of information from RNA to DNA are explicitly held possible.Retroviral RT has three sequential biochemical activities: RNA-dependent DNA polymerase activity, ribonuclease H (RNase H), and DNA-dependent DNA polymerase activity. Collectively, these activities enable the enzyme to convert single-stranded RNA into double-stranded cDNA. In retroviruses and retrotransposons, this cDNA can then integrate into the host genome, from which new RNA copies can be made via host-cell transcription. The same sequence of reactions is widely used in the laboratory to convert RNA to DNA for use in molecular cloning, RNA sequencing, polymerase chain reaction (PCR), or genome analysis.

History
Reverse transcriptases were discovered by Howard Temin at the University of Wisconsin–Madison in Rous sarcoma virions and independently isolated by David Baltimore in 1970 at MIT from two RNA tumour viruses: murine leukemia virus and again Rous sarcoma virus. For their achievements, they shared the 1975 Nobel Prize in Physiology or Medicine (with Renato Dulbecco).
Well-studied reverse transcriptases include:

HIV-1 reverse transcriptase from human immunodeficiency virus type 1 (PDB: 1HMV) has two subunits, which have respective molecular weights of 66 and 51 kDas.
M-MLV reverse transcriptase from the Moloney murine leukemia virus is a single 75 kDa monomer.
AMV reverse transcriptase from the avian myeloblastosis virus also has two subunits, a 63 kDa subunit and a 95 kDa subunit.
Telomerase reverse transcriptase that maintains the telomeres of eukaryotic chromosomes.

Function in viruses
The enzymes are encoded and used by viruses that use reverse transcription as a step in the process of replication. Reverse-transcribing RNA viruses, such as retroviruses, use the enzyme to reverse-transcribe their RNA genomes into DNA, which is then integrated into the host genome and replicated along with it. Reverse-transcribing DNA viruses, such as the hepadnaviruses, can allow RNA to serve as a template in assembling and making DNA strands. HIV infects humans with the use of this enzyme. Without reverse transcriptase, the viral genome would not be able to incorporate into the host cell, resulting in failure to replicate.

Process of reverse transcription or retrotranscription
Reverse transcriptase creates double-stranded DNA from an RNA template.
In virus species with reverse transcriptase lacking DNA-dependent DNA polymerase activity, creation of double-stranded DNA can possibly be done by host-encoded DNA polymerase δ, mistaking the viral DNA-RNA for a primer and synthesizing a double-stranded DNA by a similar mechanism as in primer removal, where the newly synthesized DNA displaces the original RNA template.The process of reverse transcription, also called retrotranscription or retrotras, is extremely error-prone, and it is during this step that mutations may occur. Such mutations may cause drug resistance.

Retroviral reverse transcription
Retroviruses, also referred to as class VI ssRNA-RT viruses, are RNA reverse-transcribing viruses with a DNA intermediate. Their genomes consist of two molecules of positive-sense single-stranded RNA with a 5' cap and 3' polyadenylated tail. Examples of retroviruses include the human immunodeficiency virus (HIV) and the human T-lymphotropic virus (HTLV). Creation of double-stranded DNA occurs in the cytosol as a series of these steps:

Lysyl tRNA acts as a primer and hybridizes to a complementary part of the virus RNA genome called the primer binding site or PBS.
Reverse transcriptase then adds DNA nucleotides onto the 3' end of the primer, synthesizing DNA complementary to the U5 (non-coding region) and R region (a direct repeat found at both ends of the RNA molecule) of the viral RNA.
A domain on the reverse transcriptase enzyme called RNAse H degrades the U5 and R regions on the 5’ end of the RNA.
The tRNA primer then "jumps" to the 3’ end of the viral genome, and the newly synthesised DNA strands hybridizes to the complementary R region on the RNA.
The complementary DNA (cDNA) added in (2) is further extended.
The majority of viral RNA is degraded by RNAse H, leaving only the PP sequence.
Synthesis of the second DNA strand begins, using the remaining PP fragment of viral RNA as a primer.
The tRNA primer leaves and a "jump" happens. The PBS from the second strand hybridizes with the complementary PBS on the first strand.
Both strands are extended to form a complete double-stranded DNA copy of the original viral RNA genome, which can then be incorporated into the host's genome by the enzyme integrase.Creation of double-stranded DNA also involves strand transfer, in which there is a translocation of short DNA product from initial RNA-dependent DNA synthesis to acceptor template regions at the other end of the genome, which are later reached and processed by the reverse transcriptase for its DNA-dependent DNA activity.Retroviral RNA is arranged in 5’ terminus to 3’ terminus. The site where the primer is annealed to viral RNA is called the primer-binding site (PBS). The RNA 5’end to the PBS site is called U5, and the RNA 3’ end to the PBS is called the leader. The tRNA primer is unwound between 14 and 22 nucleotides and forms a base-paired duplex with the viral RNA at PBS. The fact that the PBS is located near the 5’ terminus of viral RNA is unusual because reverse transcriptase synthesize DNA from 3’ end of the primer in the 5’ to 3’  direction (with respect to the newly synthesized DNA strand). Therefore, the primer and reverse transcriptase must be relocated to 3’ end of viral RNA. In order to accomplish this reposition, multiple steps and various enzymes including DNA polymerase, ribonuclease H(RNase H) and polynucleotide unwinding are needed.The HIV reverse transcriptase also has ribonuclease activity that degrades the viral RNA during the synthesis of cDNA, as well as DNA-dependent DNA polymerase activity that copies the sense cDNA strand into an antisense DNA to form a double-stranded viral DNA intermediate (vDNA). The HIV viral RNA structural elements regulate the progression of reverse transcription.

In cellular life
Self-replicating stretches of eukaryotic genomes known as retrotransposons utilize reverse transcriptase to move from one position in the genome to another via an RNA intermediate. They are found abundantly in the genomes of plants and animals. Telomerase is another reverse transcriptase found in many eukaryotes, including humans, which carries its own RNA template; this RNA is used as a template for DNA replication.Initial reports of reverse transcriptase in prokaryotes came as far back as 1971 in France (Beljanski et al., 1971a, 1972) and a few years later in the USSR (Romashchenko 1977).  These have since been broadly described as part of bacterial Retrons, distinct sequences that code for reverse transcriptase, and are used in the synthesis of msDNA. In order to initiate synthesis of DNA, a primer is needed. In bacteria, the primer is synthesized during replication.Valerian Dolja of Oregon State argues that viruses, due to their diversity, have played an evolutionary role in the development of cellular life, with reverse transcriptase playing a central role.

Structure
The reverse transcriptase employs a "right hand" structure similar to that found in other viral nucleic acid polymerases. In addition to the transcription function, retroviral reverse transcriptases have a domain belonging to the RNase H family, which is vital to their replication. By degrading the RNA template, it allows the other strand of DNA to be synthesized. Some fragments from the digestion also serve as the primer for the DNA polymerase (either the same enzyme or a host protein), responsible for making the other (plus) strand.

Replication fidelity
There are three different replication systems during the life cycle of a retrovirus. The first process is the reverse transcriptase synthesis of viral DNA from viral RNA, which then forms newly made complementary DNA strands. The second replication process occurs when host cellular DNA polymerase replicates the integrated viral DNA. Lastly, RNA polymerase II transcribes the proviral DNA into RNA, which will be packed into virions. Mutation can occur during one or all of these replication steps.Reverse transcriptase has a high error rate when transcribing RNA into DNA since, unlike most other DNA polymerases, it has no proofreading ability. This high error rate allows mutations to accumulate at an accelerated rate relative to proofread forms of replication. The commercially available reverse transcriptases produced by Promega are quoted by their manuals as having error rates in the range of 1 in 17,000 bases for AMV and 1 in 30,000 bases for M-MLV.Other than creating single-nucleotide polymorphisms, reverse transcriptases have also been shown to be involved in processes such as transcript fusions, exon shuffling and creating artificial antisense transcripts. It has been speculated that this template switching activity of reverse transcriptase, which can be demonstrated completely in vivo, may have been one of the causes for finding several thousand unannotated transcripts in the genomes of model organisms.

Template switching
Two RNA genomes are packaged into each retrovirus particle, but, after an infection, each virus generates only one provirus.  After infection, reverse transcription is accompanied by template switching between the two genome copies (copy choice recombination).  There are two models that suggest why RNA transcriptase switches templates. The first, the forced copy-choice model, proposes that reverse transcriptase changes the RNA template when it encounters a nick, implying that recombination is obligatory to maintaining virus genome integrity. The second, the dynamic choice model, suggests that reverse transcriptase changes templates when the RNAse function and the polymerase function are not in sync rate-wise, implying that recombination occurs at random and is not in response to genomic damage. A study by Rawson et al. supported both models of recombination. From 5 to 14 recombination events per genome occur at each replication cycle.  Template switching (recombination) appears to be necessary for maintaining genome integrity and as a repair mechanism for salvaging damaged genomes.

Applications
Antiviral drugs
As HIV uses reverse transcriptase to copy its genetic material and generate new viruses (part of a retrovirus proliferation circle), specific drugs have been designed to disrupt the process and thereby suppress its growth. Collectively, these drugs are known as reverse-transcriptase inhibitors and include the nucleoside and nucleotide analogues zidovudine (trade name Retrovir), lamivudine (Epivir) and tenofovir (Viread), as well as non-nucleoside inhibitors, such as nevirapine (Viramune).

Molecular biology
Reverse transcriptase is commonly used in research to apply the polymerase chain reaction technique to RNA in a technique called reverse transcription polymerase chain reaction (RT-PCR).  The classical PCR technique can be applied only to DNA strands, but, with the help of reverse transcriptase, RNA can be transcribed into DNA, thus making PCR analysis of RNA molecules possible. Reverse transcriptase is used also to create cDNA libraries from mRNA. The commercial availability of reverse transcriptase greatly improved knowledge in the area of molecular biology, as, along with other enzymes, it allowed scientists to clone, sequence, and characterise RNA.

See also
cDNA library
DNA polymerase
msDNA
Reverse transcribing virus
RNA polymerase
Telomerase
Retrotransposon marker

References
External links
RNA+Transcriptase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
animation of reverse transcriptase action and three reverse transcriptase inhibitors
Molecule of the month (September 2002) at the RCSB PDB
HIV Replication 3D Medical Animation. (Nov 2008). Video by Boehringer Ingelheim.
Goodsell DS. "Molecule of the Month: Reverse Transcriptase (Sep 2002)". Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB). Retrieved 2013-01-13.
Overview of all the structural information available in the PDB for UniProt: P03366 (Human immunodeficiency virus Reverse transcriptase) at the PDBe-KB.
TWiV 904: 50 years of reverse transcriptase Vincent Racaniello travels to Cold Spring Harbor Laboratory to speak with David Baltimore, John Coffin (scientist), and Harold Varmus about the discovery in 1970 of retroviral reverse transcriptase and its impact on life sciences research.


Revive & Restore is a nonprofit wildlife conservation organization focused on use of biotechnology in conservation. Headquartered in Sausalito, California, the organization's mission is to enhance biodiversity through the genetic rescue of endangered and extinct species. The organization was founded by Stewart Brand and his wife, Ryan Phelan.
Revive & Restore has created a "Genetic Rescue Toolkit" for wildlife conservation – a suite of biotechnology tools adapted from human medicine and commercial agriculture that can improve wildlife conservation outcomes. The toolkit includes biobanking and cell culturing, genetic sequencing, and advanced reproductive technologies, such as cloning. The toolkit complements traditional conservation practices, such as captive breeding and habitat restoration.Revive & Restore has caused controversy. In particular, Brand's work in de-extinction has been characterized as "playing god" and criticized for taking time and money away from traditional conservation efforts. In addition, many are concerned by the concept of cloning, even in the context of conservation.

History
Revive & Restore was co-founded in 2012 by Stewart Brand and Ryan Phelan with the idea of bringing biotechnology solutions to conservation. The group was incubated by the Long Now Foundation until 2017, when it became an independent 501(c)(3) organization.
In 2013 Revive & Restore organized the first public meeting on de-extinction. Their founding projects include the de-extinction of the passenger pigeon, heath hen, and woolly mammoth. Since then, Revive & Restore has established partnerships with research institutions, governmental agencies, and conservation organizations on a broad range of genetic rescue programs.Revive & Restore is a member of the International Union for Conservation of Nature (IUCN) and has long-standing partnerships with the US Fish & Wildlife Service, The San Diego Zoo Wildlife Alliance, Morris Animal Foundation, and ViaGen Pets & Equine, among others.

Programs
Advanced Coral Toolkit
The Advanced Coral Toolkit supports research teams in the development and field testing of biotechnologies that benefit coral reef management and restoration efforts. Projects include coral cryopreservation methods for large scale biobanking and fieldable devices for measuring genetic information or molecular signals associated with coral stress. Launched in 2019, the program has funded 10 research teams.

Wild Genomes
Wild Genomes is a funding program to provide genomic tools to field scientists, wildlife managers, and citizens working to protect their local biodiversity. As of 2023, Wild Genomes has funded 30 individual projects. Program categories include Terrestrial Species, Marine Species, Amphibians, and Kelp Ecosystems

Cloning for conservation
To help mitigate inbreeding depression for two endangered species, the black-footed ferret (Mustela nigripes) and Przewalski's horse (Equus ferus przewalskii), Revive & Restore facilitates on-going efforts to clone individuals from historic cell lines stored at the San Diego Zoo Wildlife Alliance Frozen Zoo.
On December 10, 2020, the world's first cloned black-footed ferret was born. This ferret, named Elizabeth Ann, marked the first time a U.S. endangered species was successfully cloned.On August 6, 2020, the world's first cloned Przewalski’s horse was born. Since the oocyte used was from a domestic horse, this was an example of interspecies somatic cell nuclear transfer (SCNT). In 2022, the horse, named Kurt, was paired with a female Przewalski's horse at the San Diego Zoo Wildlife Safari Park to learn the behaviors of his species. On February 17, 2023, a second cloned Przewalski's horse was born from the same historic cell line. Kurt and the new foal are genetic twins that may become the first cloned animals to restore lost genetic variation to their species.

Intended Consequences Initiative
In 2020, Revive & Restore developed a campaign around the concept of "Intended Consequences" – focusing on the benefits of conservation interventions, as opposed to focusing on the fears of unintended consequences. That year, Revive & Restore hosted a virtual workshop that resulted in the publication of a special issue in the journal Conservation Science and Practice.

References
External links
Official website


Right To Know is a non profit support project for those who discover via genealogical genetic testing that their lineage is not what they had supposed it to be due to family secrets and misattributed parentage,  thus raising existential issues of adoption, race, ethnicity, culture, rape, etc.

See also
Genealogy
Genetic testing

External links
Right To Know - Your Genetic Identity

== References ==


The scleraxis protein is a member of the basic helix-loop-helix (bHLH) superfamily of transcription factors.  Currently two genes (SCXA and SCXB respectively) have been identified to code for identical scleraxis proteins.

Function
It is thought that early scleraxis-expressing progenitor cells lead to the eventual formation of tendon tissue and other muscle attachments.  Scleraxis is involved in mesoderm formation and is expressed in the syndetome (a collection of embryonic tissue that develops into tendon and blood vessels) of developing somites (primitive segments or compartments of embryos).

Inducing scleraxis expression
The syndetome location within the somite is determined by FGF secreted from the center of the myotome (a collection of embryonic tissue that develops into skeletal muscle)- the FGF then induces the adjacent anterior and posterior sclerotome (a collection of embryonic tissue that develops into the axial skeleton) to adopt a tendon cell fate. This ultimately places future scleraxis-expressing cells between the two tissue types they will ultimately join. Scleraxis expression will be seen throughout the entire sclerotome (rather than just the sclerotome directly anterior and posterior to the myotome) with an overexpression of FGF8, demonstrating that all sclerotome cells are capable of expressing scleraxis in response to FGF signaling. While the FGF interaction has been shown to be necessary for scleraxis expression, it is still unclear as to whether the FGF signaling pathway directly induces the syndetome to secrete scleraxis, or indirectly through a secondary signaling pathway. Most likely, the syndetomal cells, through careful reading of the FGF concentration (coming from the myotome), can precisely determine their location and begin expressing scleraxis. Much of embryonic development follows this model of inducing specific cell fates through the reading of surrounding signaling molecule concentration gradients.

Background
bHLH transcription factors have been shown to have a wide array of functions in developmental processes. More precisely, they have critical roles in the control of cellular differentiation, proliferation and regulation of oncogenesis. To date, 242 eukaryotic proteins belonging to the HLH superfamily have been reported. They have varied expression patterns in all eukaryotes from yeast to humans.Structurally, bHLH proteins are characterised by a “highly conserved domain containing a stretch of basic amino acids adjacent to two amphipathic α-helices separated by a loop”.These helices have important functional properties, forming part of the DNA binding and transcription activating domains. With respect to scleraxis, the bHLH region spans amino acid residues 78 to 131.  A proline rich region is also predicted to lie between residues 161–170. A stretch of basic residues, which aids in DNA binding, is found closer to the N terminal end of scleraxis.HLH proteins that lack this basic domain have been shown to negatively regulate the activities of bHLH proteins and are called inhibitors of differentiation (Id). Basic HLH proteins function normally as dimers and bind to a specific hexanucleotide DNA sequence (CAANTG) known as an E-box thus switching on the expression of various genes involved in cellular development and survival.

== References ==


Ahna Renee Skop is an American geneticist, artist, and a professor at the University of Wisconsin–Madison. She is known for her research on the mechanisms underlying asymmetric cell division, particularly the importance of the midbody in this process.

Education
Skop grew up in New Haven, Connecticut and Fort Thomas, Kentucky. She graduated from Highlands High School in Fort Thomas, Ky before receiving a Bachelor of Science in biology and a minor in Ceramics from Syracuse University and went on to complete her Ph.D. in cellular and molecular biology at the University of Wisconsin-Madison. She then did postdoctoral work at the University of California, Berkeley in the laboratories of Rebecca Heald, Barbara Meyer and John Yates (Scripps). Skop then moved back to the University of Wisconsin–Madison in 2004, where, as of 2011, is a Full Professor of Genetics.

Career
Skop is known for her work on Caenorhabditis elegans, a free-living worm, and mammalian tissue culture cells where she has studied the mechanisms that control cell division. Her early work was on the final stages of cell division in C. elegans, and she identified the proteins in the midbody that are involved in cell division. Her more recent work examines defects that could be caused by problems in the midbody, where she has shown that midbody is an organelle that harbors translationally active RNA.

Artistic career
Skop has curated a scientific art show at the International C. elegans meeting, the "Worm Art Show", and she worked with a Madison, Wisconsin artist, Angela Johnson to create an art installation called "Genetic Reflections".

Select publications
Skop, Ahna R.; Bergmann, Dominique; Mohler, William A.; White, John G. (2001-05-15). "Completion of cytokinesis in C. elegans requires a brefeldin A-sensitive membrane accumulation at the cleavage furrow apex". Current Biology. 11 (10): 735–746. doi:10.1016/S0960-9822(01)00231-7. ISSN 0960-9822. PMC 3733387. PMID 11378383.
Skop, Ahna R.; Liu, Hongbin; Yates, John; Meyer, Barbara J.; Heald, Rebecca (2004-07-02). "Dissection of the Mammalian Midbody Proteome Reveals Conserved Cytokinesis Mechanisms". Science. 305 (5680): 61–66. Bibcode:2004Sci...305...61S. doi:10.1126/science.1097931. ISSN 0036-8075. PMC 3679889. PMID 15166316.
Skop, Ahna R.; White, John G. (1998-10-08). "The dynactin complex is required for cleavage plane specification in early Caenorhabditis elegans embryos". Current Biology. 8 (20): 1110–1117. doi:10.1016/S0960-9822(98)70465-8. ISSN 0960-9822. PMC 3690630. PMID 9778526.
Thompson, Heather M.; Skop, Ahna R.; Euteneuer, Ursula; Meyer, Barbara J.; McNiven, Mark A. (2002-12-23). "The Large GTPase Dynamin Associates with the Spindle Midzone and Is Required for Cytokinesis". Current Biology. 12 (24): 2111–2117. doi:10.1016/S0960-9822(02)01390-8. ISSN 0960-9822. PMC 3690653. PMID 12498685.
Otegui, Marisa S.; Verbrugghe, Koen J.; Skop, Ahna R. (2005-08-01). "Midbodies and phragmoplasts: analogous structures involved in cytokinesis". Trends in Cell Biology. 15 (8): 404–413. doi:10.1016/j.tcb.2005.06.003. ISSN 0962-8924. PMC 3677513. PMID 16009554.

Honors and awards
Skop was a 2006 Presidential Early Career Award for Scientists and Engineers award winner. In 2009 Skop received an honorary Doctorate of Science from the College of Saint Benedict, and in 2018 Skop was awarded by the American Society for Cell Biology for her work in inclusivity, the first time this prize was given.

References
External links
Ahna Skop publications indexed by Google Scholar


A SNPSTR is a compound genetic marker composed of one or more SNPs and one microsatellite (STR). Autosomal SNPSTRs, which contain an SNP and a microsatellite within 500 base pairs of one another, were discovered in 2002. More recently a database that contains all SNPSTRs in five model genomes, including human, has been created.

Usage and importance
There has been widespread and growing interest in genetic markers suitable for drawing population genetic inferences about past demographic events and to detect the effects of selection. Single nucleotide polymorphisms (SNPs) and microsatellites (or short tandem repeats, STRs) have received great attention in the analysis of human population history, even though they have both disadvantages. It was thus suggested that the combination of these two markers could give rise to better conclusions.

See also
Population genetics
Biological database
Earth Human STR Allele Frequencies Database
STR analysis
STR multiplex system
Y-STR

== References ==


The staggered extension process (also referred to as StEP) is a common technique used in biotechnology and molecular biology to create new, mutated genes with qualities of one or more initial genes.
The technique itself is a modified polymerase chain reaction with very short (approximately 10 seconds) cycles.
In these cycles the elongation of DNA is very quick (only a few hundred base pairs) and synthesized fragments anneal with complementary fragments of other strands. In this way, mutations of the initial genes are shuffled and in the end genes with new combinations of mutations are amplified.The StEP protocol has been found to be useful as a method of directed evolution for the discovery of enzymes useful to industry.

== References ==


The Strawberry Roan or Strawberry Roan may refer to:

Red or “strawberry” roan, a horse coat color
Strawberry Roan (1933 film), an American western film
Strawberry Roan, a 1932 novel by A. G. Street
Strawberry Roan (1945 film), a British drama based on the novel
The Strawberry Roan, a 1948 American western film
The Strawberry Roan (song), an American cowboy song


In genetics, a subclade is a subgroup of a haplogroup.

Naming convention
Although human mitochondrial DNA (mtDNA) and Y chromosome DNA (Y-DNA) haplogroups and subclades are named in a similar manner, their names belong to completely separate systems.

mtDNA
mtDNA haplogroups are defined by the presence of a series of single-nucleotide polymorphism (SNP) markers in the hypervariable regions and the coding region of mitochondrial DNA. They are named with the capital letters A through Z, with further subclades named using numbers and lower case letters.

Y-DNA
Y-DNA haplogroups are defined by the presence of a series of SNP markers on the Y chromosome. Subclades are defined by a terminal SNP, the SNP furthest down in the Y chromosome phylogenetic tree.

Human Y-DNA
The Y Chromosome Consortium (YCC) developed a system of naming major human Y-DNA haplogroups with the capital letters A through T, with further subclades named using numbers and lower case letters (YCC longhand nomenclature). YCC shorthand nomenclature names Y-DNA haplogroups and their subclades with the first letter of the major Y-DNA haplogroup followed by a dash and the name of the defining terminal SNP. Y-DNA haplogroup nomenclature is changing over time to accommodate the increasing number of SNPs being discovered and tested, and the resulting expansion of the Y chromosome phylogenetic tree. This change in nomenclature has resulted in inconsistent nomenclature being used in different sources. This inconsistency, and increasingly cumbersome longhand nomenclature, has prompted a move towards using the simpler shorthand nomenclature.

See also
Clade
Cladistics
Haplotype

== References ==


Syntelic attachment occurs when both sister chromosomes are attached to a single spindle pole.Normal cell division distributes the genome equally between two daughter cells, with each chromosome attaching to an ovoid structure called the spindle. During the division process, errors commonly occur in attaching the chromosomes to the spindle, estimated to affect 86 to 90 percent of chromosomes.Such attachment errors are common during the early stages of spindle formation, but they are mostly corrected before the start of anaphase.
Successful cell division requires identification and correction of any dangerous errors before the cell splits in two.
If the syntelic attachment continues, it causes both sister chromatids to be segregated to a single daughter cell.

Causes
Microtubules extend from the spindle poles and attach to the first kinetochore they encounter. Because this process is stochastic and not facilitated or directed, the first microtubules to come into contact with a kinetochore may not have originated at the correct spindle pole. Normally, the sister kinetochores are on opposing sides of the chromosomes, facing outward toward their respective spindle poles. This arrangement enhances the likelihood of properly bi-oriented chromosomes and is sometimes referred to as a mechanism for 'avoidance' of syntelic attachment. However, sometimes the kinetochores are found on the same side of the centromere, and this error cannot be corrected stochastically. Instead, the spindle must actively exert forces on one of the two kinetochores to relocate it to the proper, outer edge of the centromere. If the geometry and orientation of the two kinetochores is not corrected, the cells can still effectively achieve bi-orientation through the employment of error correction mechanisms.Polyploid cells, and tetraploids in particular, experience an increased number of syntelic attachments, which contributes to their genomic instability. This phenomenon of increased rates of syntelic attachment in polyploids is thought to result from an inability to scale the mitotic spindle and kinetochore architecture to accommodate the increase in cell size. Therefore, scaling defects between the genome and cellular architecture, which often occur in cancer, likely result in high rates of syntelic attachment.

Error Correction
Error correction is closely tied to the spindle assembly checkpoint (SAC), which oversees the progression through mitosis and can halt the cell in metaphase until proper bi-orientation of all chromosomes is achieved. Initial attachments occur randomly, and the cell destabilizes any incorrect microtubule-kinetochore interactions. Subsequent rounds of undirected attachment and destabilization occur until each kinetochore is attached to the correct spindle pole.
Tension was quickly identified as an important component of the error-sensing mechanism and likely of the spindle assembly checkpoint. Ipl1 in yeast and its functional homolog, Aurora B, in metazoans aid in tension detection and destabilization of errant attachments. Aurora B is found at the centromere, between the two kinetochores. In the absence of tension, Aurora B can phosphorylate substrates at the kinetochores, leading to destabilization of the attached microtubules. Properly attached microtubules induce tension, pulling the kinetochore far enough away from Aurora B so as to prevent phosphorylation of kinetochore components. Following destabilization, the kinetochore can form new spindle attachments, and if the new attachments result in chromosome bi-orientation, they will remain. Correct attachments that induce tension are more likely to occur when the kinetochores are geometrically positioned on opposite sides of the centromere.Robust destabilization by Ipl1/Aurora B in the absence of tension leads to a specific challenge: the initial establishment of bi-orientation, prior to the buildup of tension, would be sensitive to Ipl1/Aurora B activity. This is referred to as the initiation problem of biorientation (IPBO), and is resolved by implementing a delay between sensing the tension and destabilizing the attachment. Modeling has indicated that such a delay could be introduced if the rate of Ipl1/Aurora B kinase activity is slower than that of the counteracting phosphatase activity at the kinetochore. The time delay allows for tension to be established at bi-oriented chromosomes, so that only syntelic attachments are phosphorylated and destabilized.

Consequences
Syntelic attachment is not uncommon in early metaphase, and can often be resolved by error correction mechanisms that are well-conserved across metazoans. If syntelic attachment is left uncorrected, for example if the spindle assembly checkpoint does not successfully pause cells in metaphase, the chromosomes will not segregate correctly. This failure to properly segregate results in aneuploidy, which can lead to errors in development or cancer. Interestingly, segregation errors that result from syntelic attachment often occur without visible lagging. In contrast, merotelic attachments will cause chromosome lagging during anaphase, but will often segregate correctly and not result in aneuploidy.

See also
Spindle checkpoint
Kinetochore
Spindle apparatus

== References ==


Syntelog:  a special case of gene homology where sets of genes are derived from the same ancestral genomic region.  This may arise from speciation events, or through whole or partial genome duplication events (e.g. polyploidy).  This term is distinct from ortholog, paralog, in-paralog, out-paralog, and xenolog because it refers only to genes' evolutionary history evidenced by sequence similarity and relative genomic position.

Example
Comparison between two genomic regions of Arabidopsis thaliana derived from its most recent genome duplication event. Syntelogs are indicated by  red lines connecting regions of sequence similarly (red boxes):

Sequence analysis and visualization of syntelogs performed by GEvo..  Regerate this analysis in CoGe's GEvo using this link. GEvo Sequences were compared using the BlastZ algorithm.

See also
Synteny
Homology (biology)
Polyploidy
Comparative genomics

References
External links
[1]


Synthetic lethality is defined as a type of genetic interaction where the combination of two genetic events results in cell death or death of an organism. Although the foregoing explanation is wider than this, it is common when referring to synthetic lethality to mean the situation arising by virtue of a combination of deficiencies of two or more genes leading to cell death (whether by means of apoptosis or otherwise), whereas a deficiency of only one of these genes does not. In a synthetic lethal genetic screen, it is necessary to begin with a mutation that does not result in cell death, although the effect of that mutation could result in a differing phenotype (slow growth for example), and then systematically test other mutations at additional loci to determine which, in combination with the first mutation, causes cell death arising by way of deficiency or abolition of expression.
Synthetic lethality has utility for purposes of molecular targeted cancer therapy. The first example of a molecular targeted therapeutic agent, which exploited a synthetic lethal approach, arose by means of an inactivated tumor suppressor gene (BRCA1 and 2), a treatment which received FDA approval in 2016 (PARP inhibitor). A sub-case of synthetic lethality, where vulnerabilities are exposed by the deletion of passenger genes rather than tumor suppressor is the so-called "collateral lethality".

Background
The phenomenon of synthetic lethality was first described by Calvin Bridges in 1922, who noticed that some combinations of mutations in the model organism Drosophila melanogaster (the common fruit fly) confer lethality. Theodore Dobzhansky coined the term "synthetic lethality" in 1946 to describe the same type of genetic interaction in wildtype populations of Drosophila. If the combination of genetic events results in a non-lethal reduction in fitness, the interaction is called synthetic sickness. Although in classical genetics the term synthetic lethality refers to the interaction between two genetic perturbations, synthetic lethality can also apply to cases in which the combination of a mutation and the action of a chemical compound causes lethality, whereas the mutation or compound alone are non-lethal.Synthetic lethality is a consequence of the tendency of organisms to maintain buffering schemes (i.e. backup plans) which engender phenotypic stability notwithstanding underlying  genetic variations, environmental changes or other random events, such as mutations. This genetic robustness is the result of parallel redundant pathways and "capacitor" proteins that camouflage the effects of mutations so that important cellular processes do not depend on any individual component. Synthetic lethality can help identify these buffering relationships, and what type of disease or malfunction that may occur when these relationships break down, through the identification of gene interactions that function in either the same biochemical process or pathways that appear to be unrelated.

High-throughput screens
High-throughput synthetic lethal screens may help illuminate questions about how cellular processes work without previous knowledge of gene function or interaction. Screening strategy must take into account the organism used for screening, the mode of genetic perturbation, and whether the screen is forward or reverse. Many of the first synthetic lethal screens were performed in Saccharomyces cerevisiae. Budding yeast has many experimental advantages in screens, including a small genome, fast doubling time, both haploid and diploid states, and ease of genetic manipulation. Gene ablation can be performed using a PCR-based strategy and complete libraries of knockout collections for all annotated yeast genes are publicly available. Synthetic genetic array (SGA), synthetic lethality by microarray (SLAM), and genetic interaction mapping (GIM) are three high-throughput methods for analyzing synthetic lethality in yeast. A genome scale genetic interaction map was created by SGA analysis in S. cerevisiae that comprises about 75% of all yeast genes.

Collateral lethality
Collateral lethality is a sub-case of synthetic lethality in personalized cancer therapy, where vulnerabilities are exposed by the deletion of passenger genes rather than tumor suppressor genes, which are deleted by virtue of chromosomal proximity to major deleted tumor suppressor loci.

DDR deficiencies
DNA mismatch repair deficiency
Mutations in genes employed in DNA mismatch repair (MMR) cause a high mutation rate.  In tumors, such frequent subsequent mutations often generate "non-self" immunogenic antigens.  A human Phase II clinical trial, with 41 patients, evaluated one synthetic lethal approach for tumors with or without MMR defects.  In the case of sporadic tumors evaluated, the majority would be deficient in MMR due to epigenetic repression of an MMR gene (see DNA mismatch repair).  The product of gene PD-1 ordinarily represses cytotoxic immune responses.  Inhibition of this gene allows a  greater immune response.  In this Phase II clinical trial with 47 patients, when cancer patients with a defect in MMR in their tumors were exposed to an inhibitor of PD-1, 67% - 78% of patients experienced immune-related progression-free survival.  In contrast, for patients without defective MMR, addition of PD-1 inhibitor generated only 11% of patients with immune-related progression-free survival.  Thus inhibition of PD-1 is primarily synthetically lethal with MMR defects.

Werner syndrome gene deficiency
The analysis of 630 human primary tumors in 11 tissues shows that WRN promoter hypermethylation (with loss of expression of WRN protein) is a common event in tumorigenesis.  The WRN gene promoter is hypermethylated in about 38% of colorectal cancers and non-small-cell lung carcinomas and in about 20% or so of stomach cancers, prostate cancers, breast cancers, non-Hodgkin lymphomas and chondrosarcomas, plus at significant levels in the other cancers evaluated.  The WRN helicase protein is important in homologous recombinational DNA repair and also has roles in non-homologous end joining DNA repair and base excision DNA repair.Topoisomerase inhibitors are frequently used as chemotherapy for different cancers, though they cause bone marrow suppression, are cardiotoxic and have variable effectiveness.  A 2006 retrospective study, with long clinical follow-up, was made of colon cancer patients treated with the topoisomerase inhibitor irinotecan.  In this study, 45 patients had hypermethylated WRN gene promoters and 43 patients had unmethylated WRN gene promoters.  Irinitecan was more strongly beneficial for patients with hypermethylated WRN promoters (39.4 months survival) than for those with unmethylated WRN promoters (20.7 months survival).  Thus, a topoisomerase inhibitor appeared to be synthetically lethal with deficient expression of WRN.  Further evaluations have also indicated synthetic lethality of deficient expression of WRN and topoisomerase inhibitors.

Clinical and preclinical PARP1 inhibitor synthetic lethality
As reviewed by Murata et al., five different PARP1 inhibitors are now undergoing Phase I, II and III clinical trials, to determine if particular PARP1 inhibitors are synthetically lethal in a large variety of cancers, including those in the prostate, pancreas, non-small-cell lung tumors, lymphoma, multiple myeloma, and Ewing sarcoma.  In addition, in preclinical studies using cells in culture or within mice, PARP1 inhibitors are being tested for synthetic lethality against epigenetic and mutational deficiencies in about 20 DNA repair defects beyond BRCA1/2 deficiencies.  These include deficiencies in PALB2, FANCD2, RAD51, ATM, MRE11, p53, XRCC1 and LSD1.

Preclinical ARID1A synthetic lethality
ARID1A, a chromatin modifier, is required for non-homologous end joining, a major pathway that repairs double-strand breaks in DNA, and also has transcription regulatory roles.  ARID1A mutations are one of the 12 most common carcinogenic mutations.  Mutation or epigenetically decreased expression of ARID1A has been found in 17 types of cancer.  Pre-clinical studies in cells and in mice show that synthetic lethality for deficient ARID1A expression occurs by either inhibition of the methyltransferase activity of EZH2, by inhibition of the DNA repair kinase ATR, or by exposure to the kinase inhibitor dasatinib.

Preclinical RAD52 synthetic lethality
There are two pathways for homologous recombinational repair of double-strand breaks.  The major pathway depends on BRCA1, PALB2 and BRCA2 while an alternative pathway depends on RAD52.  Pre-clinical studies, involving epigenetically reduced or mutated BRCA-deficient cells (in culture or injected into mice), show that inhibition of RAD52 is synthetically lethal with BRCA-deficiency.

Side effects
Although treatments using synthetic lethality can stop or slow progression of cancers and prolong survival, each of the synthetic lethal treatments has some adverse side effects.  For example, more than 20% of patients treated with an inhibitor of PD-1 encounter fatigue, rash, pruritus, cough, diarrhea, decreased appetite, constipation or arthralgia.  Thus, it is important to determine which DDR deficiency is present, so that only an effective synthetic lethal treatment can be applied, and not unnecessarily subject patients to adverse side effects without a direct benefit.

See also
Synthetic genetic array
Synthetic rescue

References
External links
Data Repository of Yeast Genetic INteractions
Saccharomyces Genome Deletion Project
SynLethDB Database


The Systems Biology Ontology (SBO) is a set of controlled, relational vocabularies of terms commonly used in systems biology, and in particular in computational modeling.

Motivation
The rise of systems biology, seeking to comprehend biological processes as a whole, highlighted the need to not only develop corresponding quantitative models but also to create standards allowing their exchange and integration. This concern drove the community to design common data formats, such as SBML and CellML. SBML is now largely accepted and used in the field.  However, as important as the definition of a common syntax is, it is also necessary to make clear the semantics of models. SBO tries to give us a way to label models with words that describe how they should be used in a large group of models that are commonly used in computational systems biology. The development of SBO was first discussed at the 9th SBML Forum Meeting in Heidelberg on October 14–15, 2004. During the forum, Pedro Mendes mentioned that modellers possessed a lot of knowledge that was necessary to understand the model and, more importantly, to simulate it,  but this knowledge was not encoded in SBML. Nicolas Le Novère proposed to create a controlled vocabulary to store the content of Pedro Mendes' mind before he wandered out of the community. The development of the ontology was announced more officially in a message from Le Novère to Michael Hucka and Andrew Finney on October 19.

Structure
SBO is currently made up of seven different vocabularies:

systems description parameter (catalytic constant, thermodynamic temperature...)
participant role (substrate, product, catalyst...)
modelling framework (discrete, continuous...)
mathematical expression (mass-action rate law, Hill-type rate law...)
occurring entity representation (biochemical process, molecular or genetic interaction...)
physical entity representation (transporter, physical compartment, observable...)
metadata representation (annotation)

Resources
To curate and maintain SBO, a dedicated resource has been developed and the public interface of the SBO browser can be accessed at http://www.ebi.ac.uk/sbo.
A relational database management system (MySQL) at the back-end is
accessed through a web interface based on Java Server Pages (JSP) and JavaBeans.  Its
content is encoded in UTF-8, therefore supporting a large set of
characters in the definitions of terms.  Distributed curation is made possible
by using a custom-tailored locking system allowing concurrent access.
This system allows a continuous update of the ontology with immediate
availability and suppress merging problems.
Several exports formats (OBO flat file, SBO-XML and OWL) are generated daily or on request and can be downloaded from the web interface.
To allow programmatic access to the resource, Web Services have been implemented based on Apache Axis for the communication layer and Castor for the validation. The libraries, full documentation, samples and tutorial are available online.
The SourceForge project can be accessed at http://sourceforge.net/projects/sbo/.

SBO and SBML
Since Level 2 Version 2 SBML provides a mechanism to annotate model components with SBO terms, therefore increasing the semantics of the
model beyond the sole topology of interaction and mathematical expression.  Modelling tools such as SBMLsqueezer interpret SBO terms to augment the mathematics in the SBML file. Simulation tools can check the consistency of a rate law, convert reaction from one modelling framework to another (e.g., continuous to discrete), or distinguish between identical mathematical expressions based on different assumptions (e.g., Michaelis–Menten vs. Briggs–Haldane).  To add missing SBO terms to models, software such as SBOannotator can be used.  Other tools such as semanticSBML can use the SBO annotation to integrate individual models into a larger one.  The use of SBO is not restricted to the development of models. Resources providing quantitative experimental information such as SABIO Reaction Kinetics will be able to annotate the parameters (what do they mean exactly, how were they calculated) and determine relationships between them.

SBO and SBGN
All the graphical symbols used in the SBGN languages are associated with an SBO term. This permits, for instance, to help generate SBGN maps from SBML models.

SBO and BioPAX
The Systems Biology Pathway Exchange (SBPAX) allows SBO terms to be added to Biological Pathway Exchange (BioPAX). This links BioPAX to information useful for modelling, especially by adding quantitative descriptions described by SBO.

Organization of SBO development
SBO is built in collaboration by the Computational Neurobiology Group (Nicolas Le Novère, EMBL-EBI, United-Kingdom) and the SBMLTeam (Michael Hucka, Caltech, USA).

Funding for SBO
SBO has benefited from the funds of the European Molecular Biology Laboratory and the National Institute of General Medical Sciences.

References
External links
www.biomodels.net
Hucka M, Finney A, Sauro HM, et al. (March 2003). "The systems biology markup language (SBML): A medium for representation and exchange of Biochemical Network Models". Bioinformatics. 19 (4): 524–31. CiteSeerX 10.1.1.562.1085. doi:10.1093/bioinformatics/btg015. PMID 12611808.
Lloyd CM, Halstead MD, Nielsen PF (2004). "CellML: its future, present and past". Prog. Biophys. Mol. Biol. 85 (2–3): 433–50. CiteSeerX 10.1.1.460.934. doi:10.1016/j.pbiomolbio.2004.01.004. PMID 15142756.


Tafazzin is a protein that in humans is encoded by the TAFAZZIN gene. Tafazzin is highly expressed in cardiac and skeletal muscle, and functions as a phospholipid-lysophospholipid transacylase (it belongs to phospholipid:diacylglycerol acyltransferases). It catalyzes remodeling of immature cardiolipin to its mature composition containing a predominance of tetralinoleoyl moieties. Several different isoforms of the tafazzin protein are produced from the TAFAZZIN gene. A long form and a short form of each of these isoforms is produced; the short form lacks a hydrophobic leader sequence and may exist as a cytoplasmic protein rather than being membrane-bound. Other alternatively spliced transcripts have been described but the full-length nature of all these transcripts is not known. Most isoforms are found in all tissues, but some are found only in certain types of cells. Mutations in the TAFAZZIN gene have been associated with mitochondrial deficiency, Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, left ventricular noncompaction (LVNC), breast cancer, papillary thyroid carcinoma, non-small cell lung cancer, glioma, gastric cancer, thyroid neoplasms, and rectal cancer.It is important to note that the TAZ gene was frequently confused with a protein called TAZ (transcriptional coactivator with PDZ-binding motif, a 50 kDA protein). which is a part of the Hippo pathway and entirely unrelated to the gene of interest. The Hippo pathway TAZ protein has an official gene symbol of WWTR1.

Structure
The TAFAZZIN gene is located on the q arm of chromosome X at position 28 and it spans 10,208 base pairs. The TAFAZZIN gene produces a 21.3 kDa protein composed of 184 amino acids. The structure of the encoded protein has been found to differ at their N terminus and the central region, which are two functionally notable regions. A 30 residue hydrophobic stretch at the N terminus may function as a membrane anchor, which does not exist in the shortest forms of tafazzins. The second region is a variable exposed loop located between amino acids 124 and 195 in the central region. This hydrophilic region is known to interact with other proteins. TAZ has no known resemblance to other proteins. The half-life of tafazzin is just 3–6 hours, considerably shorter than most mitochondrial proteins, which may explain research difficulties in studying its structure.The putative phospholipid-binding site, which is the active site of Tafazzin, is a 57 amino acid cleft with two open ends and positively charged residues. In addition, tafazzin localizes to the membrane leaflets facing the intermembrane space (IMS), which is crucial for remodeling. Tafazzin differs from phospholipases in that it contains a conserved histidine residue, His-77, as part of the conserved HX4D motif seen in acyltransferases. This motif is responsible for facilitating the Asp-His dyad mechanism seen in many serine proteases. Many unique forms of tafazzin have been identified, with lengths from 129 to 292 amino acids. Tafazzin has at least four different isoforms. It has a molecular weight around 35 kDa but may also appear in lower molecular weights due to species differences in isoform expression. Seven functional classes of TAFAZZIN mutations have been classified based on the pathogenic loss-of-function mechanisms of each mutation.The TAFAZZIN gene contains two peptides independent of its active site for directing the protein to the mitochondria, forming residues 84–95 in exon 3 and residues 185–200 in exon 7/8 targets. Tafazzin localizes with peripheral association to membrane leaflets between the inner mitochondrial membrane (IMM) and outer mitochondrial membrane (OMM), facing the intermembrane space (IMS). Tafazzin's characteristic interfacial anchoring is achieved by its hydrophobic sequence from residues 215–232. Finally, the translocase of the outer membrane (TOM) and the translocase of the inner membrane (TIM) mediates tafazzin's movement and insertion into the OMM and anchoring to IMM.

Function
The TAFAZZIN gene provides instructions for producing a protein called tafazzin, which is localized to mitochondria, the energy-producing centers of cells. Tafazzin transacylase activity is responsible for cardiolipin remodeling, critical to maintaining mitochondrial inner membrane structure and function. It also has unique acyl specificity and membrane curvature sensing capabilities.

Transacylase (remodeling)
After its synthesis, cardiolipin cannot exert its proper functions until it is actively remodeled. Tafazzin, an acyl-specific transferase, catalyzes the acyl transfer reaction between phospholipids and lysophospholipids in a CoA-independent manner. The remodeling process of cardiolipin involves reaching a final acyl composition that is primarily linoleoyl residues. TAZ interacts with an immature cardiolipin by adding the fatty acid linoleic acid, which catalyzes the remodeling of the cardiolipin. The remodeling is achieved by transacylation or the deacylation-reacylation cycle. The deacylation-reacylation cycle, also known as the Lands cycle, begins with deacylation mediated by phospholipase Cld1 to form monolysocardiolipin (MLCL).  MLCL is reacylated by tafazzin in a single-step reaction which transfers a linoleic acid group from phosphatidylcholine (PC), completing the CL deacylation-reacylation cycle. In contrast, transacylation involves the transfer of a linoleic acid group from phosphatidylcholine (PC) to MLCL. Such enzymatic activity forms lyso-PC and CL, and enriches the specific acyl chain of cardiolipin. The process has been shown to be specific for linoleoyl-containing PC. Such remodeling processes converts cardiolipin into a mature composition that contains a predominance of tetralinoleoyl moieties. CL remodeling in mammals requires additional enzymes, such as monolysocardiolipin acyltransferase (MLCLAT), acyl-CoA:lysocardiolipin acyltransferase (ALCAT), and phospholipase. The process enables the proper function of cardiolipin.

Acyl specificity and sensing curvature
Tafazzin in CL remodeling has been shown to have a clear preference for linoleoyl-containing PC in forming mature CL. This specificity leads a mature composition of CL that contains a predominance of tetralinoleoyl moieties, which leads to the enrichment of tetralinoleoyl-cardiolipin (CL4). The preference for lineoyl groups has been reported to be ten times greater than that of oleoyl groups and twenty times greater than that of arachidonoyl groups. Conflicting explanations for this preference have included causation from energy minimization with influences by the surrounding microenvironment, known as the thermodynamic remodeling hypothesis, or the inherent enzymatic preference of tafazzin for specific acyl residues.

Tafazzin and cardiolipin in mitochondrial structure and function
Cardiolipin is a complex glycerophospholipid which contains four acyl groups linked to three glycerol moietie localized in the mitochondrial inner membrane. These acyl groups include oleic acid and linoleic acid. Due to this composition, cardiolipin exhibits a conical structure, which allows for membrane curvature called cristae. Further, CL plays important roles in oxidative phosphorylation by stabilizing the chain complexes with its linkages between acyl chains, binding to the c-rings of ATP synthase for proper function, maintaining respiratory chain supercomplex formation with proteins localized in the inner mitochondrial matrix including ATP/ADP translocase, pyruvate carrier, carnitine carrier, and all of the respiratory chain complexes (I, III, IV, V). Cardiolipin also facilitates proton trapping in the intermembrane space to aid ATP synthase in channeling protons into the mitochondrial matrix. Properly formed CL is critical in maintaining mitochondrial shape, energy production, and protein transport within cells, and remodeling by tafazzin aids in removing and replacing acyl chains damaged by oxidative stress. During apoptosis and similar processes, CL is known to act as a platform for proteins and other machinery involved with its interactions with members of the Bcl-2 family, caspases, Bid, Bax, and Bak.

Clinical significance
Mutations in the TAFAZZIN gene have been associated with a number of mitochondrial deficiencies and associated disorders including Barth syndrome, dilated cardiomyopathy (DCM), hypertrophic DCM, endocardial fibroelastosis, and left ventricular noncompaction (LVNC). TAFAZZIN has also been associated with various cancers, including breast cancer, papillary thyroid carcinoma and non-small cell lung cancer, glioma, gastric cancer, thyroid neoplasms, and rectal cancer.

Barth syndrome
Barth syndrome (BTHS) is an X-linked disease caused by mutations in the TAFAZZIN gene. More than 160 mutations in the TAFAZZIN gene have been linked to this disease. It is a rare disease, found in 1 out of every 300,000 to 400,000 live births, though it is widely known that the disease is underdiagnosed. Although BTHS occurs almost exclusively in males, there has been one identified case of BTHS in a female patient. Tafazzin is responsible for remodeling of a phospholipid cardiolipin (CL), the signature lipid of the mitochondrial inner membrane. TAFAZZIN gene mutations that cause Barth syndrome result in the production of tafazzin proteins with little or no function. As a result, linoleic acid is not added to cardiolipin, which disrupts normal mitochondrial shape and function, including energy production and protein transport. Barth syndrome patients exhibit defects in cardiolipin metabolism, including aberrant cardiolipin fatty acyl composition, accumulation of monolysocardiolipin (MLCL), and reduced total cardiolipin levels. This may lead to acute metabolic decompensation and sudden death.  Tissues with high energy demands, such as the heart and other muscles, are most susceptible to cell death due to reduced energy production in mitochondria and protein transport.Additionally, affected white blood cells have abnormally shaped mitochondria, which could impair their ability to grow (proliferate) and mature (differentiate), leading to a weakened immune system and recurrent infections. Dysfunctional mitochondria likely lead to other signs and symptoms of Barth syndrome.Phenotypes of Barth Syndrome encompass a wide range, with cardiovascular, musculoskeletal, neurological, metabolic, and hematologic consequences. Common clinical manifestations include:
dilated cardiomyopathy (enlarged and weakened heart)
muscle weakness
recurrent infections
short stature
endocardial fibroelastosis
growth retardation
neutropenia
organic aciduria (3-methylglutaconic acid)Additional features include hypertrophic cardiomyopathy, isolated noncompaction of left ventricular myocardium (INVM), ventricular arrhythmia, motor delay, poor appetite, fatigue and exercise intolerance, hypoglycemia, lactic acidosis, hyperammonemia, and dramatic late catch-up growth after growth delay throughout childhood.A c.348C>T mutation resulted in dilated cardiomyopathy with noncompaction of the ventricular myocardium. A patient with a frame shift mutation of c.227delC displayed symptoms of neutropenia, cardiomegaly, and other common symptoms of Barth syndrome. Another c.C153G mutation resulted in severe metabolic acidosis, cardiomegaly, and other major symptoms of Barth syndrome.There is no known cure for BTHS, and treatment of BTHS is convoluted and delayed due to the disease's varying phenotypes and its sheer complexity. Thus, many treatments focus on cardiovascular and metabolic disorders, rather than treating the symptom itself. Elamipretide, an agent which protects CL from oxidative damage to maintain mitochondrial cristae and oxidative phosphorylation, is currently being tested in clinical trials. Further, dietary fatty acids have been used to enhance bioenergetics and cardiac function in BTHS. However, severe manifestations of the symptoms in BTHS patients require heart transplantation. Statistics show 9 out of 73 (12%) surviving patients who have undergone cardiac transplantation at the last update. Heart transplantation in BTHS patients has generally been successful.

Cardiovascular pathology
Cardiomyopathy is a prominent feature of Barth syndrome. The change in acyl chain composition and lipid peroxidation caused by defective tafazzin can cause defective sarcomeric action, which may lead to an insufficient power stroke, severely weakened tissue, enlarged left ventricle, partial or incomplete contraction, and decreased ejection volume. Such consequences contribute to the cardiomyopathic phenotypes of Barth syndrome, marked by a weakened heart and diminished contractility. Alternatively, reactive oxygen species (ROS) has been suggested as the primary cause of cardiovascular impairments in BTHS.Cardiomyopathy in BTHS is exhibited at varying levels. A cohort study of BTHS patients showed 41.5% of all diagnosed cardiomyopathies in the range from birth to one month of age, and 95% exhibited a history of cardiomyopathy. Furthermore, there have been cases with mild or late-onset cardiomyopathies, such as two infantile patients without cardiomyopathic phenotypes at the time of diagnosis. Cardiomyopathy in Barth syndrome is primarily exhibited in multiple forms, including dilated cardiomyopathy (DCM), left ventricular condition in which the heart becomes weakened and enlarged, and therefore cannot pump blood efficiently. The resulting decrease in blood flow can lead to swelling in the legs and abdomen, fluid in the lungs, and an increased risk of blood clots. Some mutations in the TAFAZZIN gene cause dilated cardiomyopathy without the other features of Barth syndrome. LVNC is a condition in which the left ventricle, characterized by a spongy structure on the ventricular wall, exhibits prominent trabeculations and deep intertrabecular recesses. INVM occurs when the lower left chamber of the heart (left ventricle) does not develop correctly. In INVM, the heart muscle is weakened and cannot pump blood efficiently, frequently causing heart failure. Abnormal heart rhythms (arrythmias) can also occur.

Musculoskeletal pathology
Musculoskeletal pathology is exhibited in varying forms in BTHS patients. A common phenotype is both generalized and local weakness. Weakness is exhibited as overt muscle weakness and increased exertional fatigue due to skeletal myopathy. It worsens when present with the cardiovascular symptoms of Barth syndrome. Additional symptoms of musculoskeletal pathology include hypotonia, delayed motor development, short stature, and facial dysmorphia in varying degrees. Furthermore, it has been shown that a downshift in weight, length, and height relative to the normal population is exhibited in BTHS patients.Treatment for developmental delays have included cornstarch supplementation as an alternative source of glucose. Metabolic deficiencies have been treated by oral arginine and carnitine supplementation, which has been shown to ameliorate cardiac function and muscle weakness in some patients. However, no formal assessment of the utility of carnitine and arginine supplementation has been published, and its uses have only been effective in patients with specific deficiencies.

Neurological pathology
Cognitive impairments are common in BTHS patients in varying degrees. While a higher incidence of cognitive impairment and mild learning and speech difficulties are often manifested, many BTHS patients have also displayed normal cognitive abilities. This shows the limited neurologic involvement in BTHS, despite tafazzin's crucial roles in brain mitochondrial respiration and normal cognitive function. One study has shown that the brain has a distinct CL composition, with more diverse and less tetralinoleoyl-dependent CL. This composition diminishes the need for CL remodeling, resulting in a less tafazzin-dependent composition. Another study found that the brain has a higher concentration of saturated acyl chains. Finally, the brain has a higher ROS scavenging capability, which allows the circumvention of the harmful effects of ROS. These findings explain the neurological phenotypes in BTHS patients.

Metabolic disorders
Metabolic disorders in BTHS are exhibited in the form of 3-methylglutaconic aciduria (3-MGA), a condition characterized by increased levels of organic acids in urine, including 3‐methylglutaconic acid, 3‐methylglutaric acid, and 2‐ethyl-hydracrylic acid. While 3-MGA is largely excreted in BTHS patients, some patients have been found to have normal levels of organic acids in urine. Treatment of 3-MGA and metabolic deficiencies have included riboflavin or coenzyme Q10, which have shown significant improvement in patients.

Hematologic pathology
The major hematologic pathology for BTHS patients is neutropenia, a condition characterized by a decline in total number of neutrophils in circulation with an increase in monocytes and eosinophils and no fluctuations in lymphocytes. Presentation of neutropenia varies from mild to severe, cyclical to non-cyclical, and intermittent to chronic. An absolute neutrophil count of < 500/μL, defined as severe chronic neutropenia (SCN), is the most deleterious form.

Cancer
TAFAZZIN has been found to be highly expressed in gastric cancer cells resistant to cisplatin. This resistance was identified to be due to the acquired ability of the cancer cells to undergo epithelial-mesenchymal transition (EMT). The findings that TAFAZZIN is involved in inducing EMT as well as its high levels in these cancer cells may point to its involvement in gastric cancer.  TAFAZZIN overexpression has been linked to rectal cancer, prostate cancer, thyroid neoplasm, and cervical cancer. In a study of 140 Swedish rectal cancer patients, TAFAZZIN overexpression was associated with an increase in the expression of oncogenes (FXYD-3 and Livin). It was also found to enhance cell anti-apoptosis response and abnormal cell growth and was even found to be an indicator of rectal cancer's stage, type, and progression. Additionally, the levels of TAFAZZIN were connected to the radiotherapy response of the patients, potentially offering insight into cancer recurrence in patients. A potential link between PI3K and TAFAZZIN indicates a possible association between PI3K signaling and TAFAZZIN as both were highly elevated in PTEN mutant cancer cells. In prostate cancer, CL, which is remodeled by tafazzin, was shown to have high palmitoleic acid content, which was found to have the ability to stimulate prostate cancer cell proliferation and reduce the rate of apoptosis. In thyroid neoplasm, TAFAZZIN allows follicular adenomas to be distinguished from follicular carcinomas, while in cervical cancer tafazzin levels increased from normal tissue, to squamous intraepithelial lesions, to squamous cervical carcinoma. Based on studies of cervical cancer progression, it is believed that TAFAZZIN may induce cancer by inhibiting apoptosis and promoting cancer cell growth, viability, and tumorigenesis.

Interactions
Tafazzin has been shown to have protein-protein interactions with the following and more.
FUT11
BTRC
NAGA
NID2
ANKRD46
VWDE
ITGA8

History
The protein was discovered in 1996 by Italian scientists Silvia Bione et al.. Owing to the complex procedure required for the identification of tafazzin, the protein was named after Tafazzi, an Italian comedy character who enthusiastically beats his groin with a plastic bottle.

Notes
References
Further reading
External links
GeneReviews/NCBI/NIH/UW entry on Dilated Cardiomyopathy Overview
TAZ+protein,+human at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
This article incorporates text from the United States National Library of Medicine, which is in the public domain.


Ubiquitin-Protein Ligase E3B (UBE3B) is an enzyme encoded by UBE3B gene in humans. UBE3B has an N-terminal IQ motif, which mediates calcium-independent calmodulin binding and a large C-terminal catalytic HECT domain.

Discovery
UBE3B gene was discovered in 1996 by the group of Margaret Lomax at the University of Michigan Medical School. Differential mRNA expression study, to reveal genes upregulated after acoustic trauma in the chick basilar papilla, led to identification of cDNA which exhibited 84% of identity of uncharacterized human cDNA. Interestingly, its expression dramatically increased in the regions of damaged chick inner ear upon noise-induced trauma. In 2003, human and mouse UBE3B gene was cloned and characterized by its discoverers.

Clinical significance
Inactivating mutations in UBE3B gene have been linked to Kaufman oculocerebrofacial syndrome (KOS), a severe developmental disorder. Most mutations are loss-of-function and lead to premature stop codon. However, some mutations are of single amino acid substitution type and these occur in the low complexity region, or in the catalytic HECT domain.

Mouse models
Deletion of murine ortholog Ube3b leads to severe developmental delay in mice. The conventional knockout of Ube3b leads to a growth retardation, decreased grip strength, and loss of vocalization associated with the metabolic disease with nucleotide metabolism and the tricarboxylic acid cycle being the most affected. Such metabolic disturbances were also found in KOS patients. In this context, UBE3B ubiquitinated α-ketoacid dehydrogenase kinase (BCKDK). Forebrain-specific conditional Ube3b knockout mice showed impaired spatial learning, altered social interactions, and repetitive behaviors. Ube3b knockout neurons exhibited decreased dendritic branching, increased density and aberrant morphology of dendritic spines, altered synaptic physiology, and changes in hippocampal circuit activity. Dendritic and spine phenotype was regulated by Ube3b in a cell-autonomous manner. Murine Ube3b ubiquitinated the catalytic γ-subunit of calcineurin, Ppp3cc, the overexpression of which phenocopied Ube3b loss with regard to dendrite branching and dendritic spine density.

== References ==


The universal stress protein (USP) domain is a superfamily of conserved genes which can be found in bacteria, archaea, fungi, protozoa and plants. Proteins containing the domain are induced by many environmental stressors such as nutrient starvation, drought, extreme temperatures, high salinity, and the presence of uncouplers, antibiotics and metals.In the presence of these stressors, Usp genes are upregulated resulting in large quantities of Usp proteins being produced by the cell. The over production of USP genes allows the organisms to better cope with stresses by largely unknown mechanisms. However, the USPs will alter the expression of a variety of genes that help to cope with stress.

Function
The primary function of this superfamily is to protect the organism from environmental stress such as exposure to UV light, which may induce genes containing the USP domain in order to protect the DNA and more generally the cell from further damage. During bacterial starvation the USP genes upregulated will often arrest cell growth and promote its metabolism to adapt to sparse nutrients.Recent research also suggests proteins containing this domain have functions beyond the realms of dealing with environmental stresses. Nachin et al. demonstrated in Escherichia coli that USPs are involved in actions such as adhesion and motility. The researchers, through means of "knocking out" USP genes known as UspE and UspC, saw results suggesting an inability to swim and completely lack of motility, respectively. Conversely, mutants for genes UspF and UspG were shown to have enhanced swimming abilities. Therefore, mobility is affected both positively and negatively USPs within E. coli. This demonstrates USPs influence throughout the cell could be widespread for a number of reasons.
Additionally, in Halmonas elongate, there is a USP called TeaD has been described as a key regulator in the transport of Ectoine across the cell membrane. This demonstrates how versatile USPs can be. Their function, while primarily encompasses increasing survival during stressful conditions, is not always limited to this.

Evolution
The ubiquitous nature of these proteins suggests the domain evolved in an ancestral species as well as highlighting the clear biological significance these proteins have in order to  still be present in the three domains of life. It has been suggested that the USP A domain was part of an ancient protein family. This is due to the similarity in structure between many distantly related organisms. Aravind et al. confirmed these ideas with extensive evolutionary analysis. Aravind suggested that these proteins were part of a much larger protein structural family which was present and diversified in our last universal common ancestor for all extant life.
The original function has been suggested to be a nucleotide binding domain which was implicated in signal transduction

Structure
As the USP domain is widespread across many organisms, there is great diversity in the structures of these proteins. For Haemophilus influenzae, its UspA resides in the cytoplasm. The protein forms an asymmetric dimer with characteristic alpha and beta fold structures. There are differences among different bacteria in areas such as ATP binding sites. In this case, UspA does not have ATP binding activity. Generally, USPs form dimers and have domains for nucleotide binding activity. However, as it is such a diverse group, often with little known about the exact structure, it’s not possible to comment on each USP. In addition to this, UspA may reside in different areas of the cell. For example, in this case it was in the cytoplasm but for others, it may be in the cell membrane.

Bacteria
Much of the research into USP is done on bacteria, specifically E. coli (Strain K-12). Consequently, much is known about the USP domains in bacteria. In E. coli there are six families of USP domains which are present in more than 1000 different proteins. The six families are Usp A, -C, -D, -E, -F and –G which are triggered by differing environmental insults and often act via varying mechanisms.UspA is the most commonly studied USP due to its widespread presence within bacterial genomes. UspA is especially implicated in the resistance of a huge number of stressors most notably tetracycline exposure and high temperatures, with the exception of not forming a response to cold shock. It is thought UspA is especially important to the recovery of E. coli following starvation of nutrients.  UspA during normal growth conditions does not seem to influence gene expression. However, during stressful conditions such as carbon starvation, UspA has been shown to have a global influence on gene expression. A proposed mechanism for such a change in gene expression is that UspA has been suggested to bind to DNA. When UspA is mutated, E. coli becomes far more vulnerable UV induced DNA damage.
It’s important to note the USP responses are independent of many other stress responses seen in bacteria such as rpoS.
The induction of USP proteins have also been implicated in transitions not only in metabolism or growth but in changes in the colonies' entire phenotype. Bacterial colonies can produce formations known as biofilms. Zhang and colleagues demonstrated that USPs may be involved in the promotion of intertidal biofilms. They observed that during stressful conditions involving metal ions and oxidative stresses that the biofilm phenotype would form. Upon analysis of these biofilms, it could be seen that there was a greatly upregulated level of UspA which Zhang suggests, may be involved with induction of biofilm formation. It is thought UspA may be involved in signalling processes which will upregulate genes involved with biofilm production. With findings such as these, it's beginning to be accepted that USPs are acting using an extremely wide range of mechanisms to ensure cell survival.

Regulation
In bacteria, the USP genes can be regulated by sigma factors within RNA polymerases. This includes sigma factor σ70 which through binding to a single promoter region, upregulates the transcription of UspA in bacteria. The genes are regulated in a monocistronic fashion.
Additionally, UspA, UspC, UspD and UspE are over induced during stationary phase through regulation of RecA. RecA is known for its involvement in the repair of DNA via homologous recombination following damage. Consequently, the four Usp domain genes are thought to be mediating the management or protection of DNA. Whatever the mechanism exhibited by the proteins, one thing which can be concluded is that USP domains are crucial for survival of many bacterial species. Gomes et al. found that UspA deletions in Listeria severely impaired survival as well as listeria’s stress response by in vitro and in vivo.USP domain genes are regulated by a number of proteins involved with growth, DNA repair and cell division. Notable positive regulation occurs via the action of ppGpp, RecA and FtsZ dependent regulatory pathways. USP domain genes are also under the negative control of FadR.

Plants
Plants contain many hundreds of USP domains and genes. These genes are notably induced by environmental stresses such as drought. When a lack of hydration occurs, biochemical changes induced by the actions of USPs ensue. In response to drought, there is a reduction in photosynthetic carbon production as well as a reduction in energy metabolism. These actions are suggested to occur due to their implications in increasing energy conservation. Water limiting conditions are a common environmental pressure which plants will need to cope with on a regular basis, depending on their habitat. These resistant phenotypes will have an increased survival as they allow the plant to conserve energy in times of restricted water which is key to glucose production through photosynthesis.

Clinical significance
Tuberculosis
Mycobacterium tuberculosis, the infectious agent responsible for tuberculosis (TB), persists within an estimated two billion people. TB is known for its ability to transition into a latent state whereby there is slow growth but high persistence within the mammalian host in structures known as granulomas. These granuloma structures are made up of various cellular materials and immune cells. These include macrophages, neutrophils, cellulose and fats. It has long been proposed that USPs play a significant role in the persistence of TB within the human host. This is due to observations of elevated Usp genes within M. tuberculosis in the latent granuloma stage of the infection.There are eight types of USPs within M. tuberculosis, all of which have an ATP binding domain. It has been found that within M. tuberculosis, these USPs are regulated by FtsK and FadR. One recent finding shows that the induction of USPs within M. tuberculosis results in USP binding activity with intracellular cAMP which has indirect implications on transcription within the bacteria.Some of M. tuberculosis' USPs are suggested to be induced by the hypoxic conditions found within the granuloma. Specifically, Rv2623, a type of USP in M. tuberculosis, is induced by the presence of nitric oxide, reactive oxygen species and a downshift in pH. All of these conditions are suggested to be produced by the actions of macrophages which are particularly prevalent within the granuloma structures that are characteristic of TB latent infections.  These conditions have been found to upregulate a particular USP gene called rv2623, as well as an additional 50 genes involved in long-term persistence in the mammalian host. It was suggested this USP gene was involved in inducing the latent response within the mammalian host. This stage of the infection is currently chronic with no effective treatments. This makes these kinds of findings extremely valuable.
Rv2623 has an ATP binding domain which if knocked out results in a hyper-virulent form of the bacteria. Understanding these processes aids researchers in their quest to provide effective treatment for those suffering from TB. Rv2623 is also a key biomarker aiding the diagnostic process for TB. Therefore, these USP genes could be crucial for the long-term survival of the bacteria, meaning that there may be potential therapeutic avenues of research to explore in treating latent TB. This comes at a time whereby TB kills many thousands of people a day and is becoming increasing problematic to treat with the rise of multi-drug-resistant TB.

Salmonella
Similarly, USPs are crucial for the survival of Salmonella, the causative agent in Salmonellosis. In developing countries, food poisoning of this kind is a potentially life-threatening condition. The USPs have influence in growth arrest, stress responses and virulence. UspA is induced by metabolic, oxidative and temperature related stress. In these conditions UspA is over produced through the transcriptional regulation by ppGpp and RecA. These responses have been suggested to be involved in the protection of DNA. As a result, UspA aids Salmonella to resist stressors produced by the mammalian immune system assisting in survival and hence, pathogenicity. When UspA is inactivated in Salmonella, the mutants die prematurely, demonstrating how crucial these proteins are to survival and persistence. Again, understanding these processes may aid researchers in developing effective drugs to treat these infections.

References
External links
WikiGenes: UspA - The universal stress regulator
PortEco: Gene Database - UspA
PDB UspA Structure
EMBL-EBI Pfam for UspA


An upstream activating sequence or upstream activation sequence (UAS) is a cis-acting regulatory sequence. It is distinct from the promoter and increases the expression of a neighbouring gene. Due to its essential role in activating transcription, the upstream activating sequence is often considered to be analogous to the function of the enhancer in multicellular eukaryotes. Upstream activation sequences are a crucial part of induction, enhancing the expression of the protein of interest through increased transcriptional activity. The upstream activation sequence is found adjacently upstream to a minimal promoter (TATA box) and serves as a binding site for transactivators. If the transcriptional transactivator does not bind to the UAS in the proper orientation then transcription cannot begin. To further understand the function of an upstream activation sequence, it is beneficial to see its role in the cascade of events that lead to transcription activation. The pathway begins when activators bind to their target at the UAS recruiting a mediator. A TATA-binding protein subunit of a transcription factor then binds to the TATA box, recruiting additional transcription factors. The mediator then recruits RNA polymerase II to the pre-initiation complex. Once initiated, RNA polymerase II is released from the complex and transcription begins.

Examples
GAL1-GAL10 intergenic region (UASG)
The property of the GAL1-GAL10 to bind the GAL4 protein is utilised in the GAL4/UAS technique for controlled gene mis-expression in Drosophila. This is the most popular form of binary expression in Drosophila melanogaster, a system which has been adapted for many uses to make Drosophila melanogaster one of the most genetically tractable multicellular organisms. In this technique, four related binding sites between the GAL10 and GAL1 loci in Saccharomyces cerevisiae serve as an Upstream Activating Sequences (UAS) element through GAL4 binding. Several studies have been conducted with Saccharomyces cerevisiae to explore the exact function of upstream activation sequences, often focusing on the aforementioned GAL1-GAL10 intergenic region. The consensus is 5′-CGG-N11-CCG-3′.One study explored the galactose-responsive upstream activation sequence (UASG), looking at the influence of proximity to this UAS for nucleosome positioning. Proximity to the UAS was chosen because deletions of DNA flanking the UAS left the nucleosome array unaltered, indicating that nucleosome positioning was not related to sequence-specific histone-DNA interactions. The role of specific regions of UASG was analyzed by inserting oligonucleotides with different binding properties, leading to the successful identification of a region responsible for the creation of an ordered array. The sequence identified overlapped a binding site for GAL4 protein, which is a positive regulator for transcription which coincides with the function of upstream activating sequences.Another study looked at the effect of inserting the UASG into the promoter region of the glyceraldehyde-3-phosphate dehydrogenase gene (GPD) [1]. This hybrid promoter was then utilized to express human immune interferon, a toxic substance to yeast that results in a reduced copy number and low plasmid stability. Relative to the native promoter, expression of the hybrid promoter was induced roughly 150- to 200-fold in the cultures by growth in galactose, induction that wasn't apparent with glucose as the carbon source. When compared to the native GPD promoter, the presence of UASG caused the transcriptional activity to remain equivalently enhanced under induced conditions.

Inositol-sensitive upstream activation sequence (UASINO)
The inositol-sensitive upstream activation sequence (UASINO) has a consensus sequence 5'-CATGTGAAAT-3' and is present in the promoter regions of genes that encode enzymes of phospholipid biosynthesis. These enzymes are regulated by inositol and choline, both of which are phospholipid precursors. Within this consensus sequence, the first six bases are homologous with canonical binding motif for proteins within the bHLH or the basic helix-loop-helix family. Studies have shown that Ino2p and Ino4p, two bHLH regulatory proteins from Saccharomyces cerevisiae, bind to promoter fragments containing this element of the consensus sequence. Additional studies have been designed to explore the function of UASINO in more detail largely in part because a large number of phospholipid biosynthetic enzyme activities in the model organism Saccharomyces cerevisiae show this common pattern of expression.One study explored the interaction between Ino4p and Ino2p in more depth, examining the dimerization that takes place between the two prior to binding to the promoter of the INO1 gene and activating transcription. By isolating 31 recessive suppressors of the ino4-8 mutant of yeast and determining that 29 were of the same locus, the researchers identified the locus as REG1 [2]. One allele of REG1, the suppressor mutant sia1-1, was capable of suppressing the inositol auxotrophy, revealing a possible pathway for the repression of inositol-sensitive upstream activating sequence-containing genes of yeast.

== References ==